Emma C. Tallantyre
COVID-19 Vaccine Response in People with Multiple Sclerosis
Tallantyre, Emma C.; Vickaryous, Nicola; Anderson, Valerie; Asardag, Aliye Nazli; Baker, David; Bestwick, Jonathan; Bramhall, Kath; Chance, Randy; Evangelou, Nikos; George, Katila; Giovannoni, Gavin; Godkin, Andrew; Grant, Leanne; Harding, Katharine E.; Hibbert, Aimee; Ingram, Gillian; Jones, Meleri; Kang, Angray S.; Loveless, Samantha; Moat, Stuart J.; Robertson, Neil P.; Schmierer, Klaus; Scurr, Martin J.; Shah, Sita Navin; Simmons, Jessica; Upcott, Matthew; Willis, Mark; Jolles, Stephen; Dobson, Ruth
Authors
Nicola Vickaryous
Valerie Anderson
Aliye Nazli Asardag
David Baker
Jonathan Bestwick
Kath Bramhall
Randy Chance
NIKOS EVANGELOU Nikos.Evangelou@nottingham.ac.uk
Clinical Professor
Katila George
Gavin Giovannoni
Andrew Godkin
Leanne Grant
Katharine E. Harding
Aimee Hibbert
Gillian Ingram
Meleri Jones
Angray S. Kang
Samantha Loveless
Stuart J. Moat
Neil P. Robertson
Klaus Schmierer
Martin J. Scurr
Sita Navin Shah
Jessica Simmons
Matthew Upcott
Mark Willis
Stephen Jolles
Ruth Dobson
Abstract
Objective: The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple sclerosis (MS). Methods: Four hundred seventy-three people with MS provided one or more dried blood spot samples. Information about coronavirus disease 2019 (COVID-19) and vaccine history, medical, and drug history were extracted from questionnaires and medical records. Dried blood spots were eluted and tested for antibodies to SARS-CoV-2. Antibody titers were partitioned into tertiles with people on no disease modifying therapy as a reference. We calculated the odds ratio of seroconversion (univariate logistic regression) and compared quantitative vaccine response (Kruskal Wallis) following the SARS-CoV-2 vaccine according to disease modifying therapy. We used regression modeling to explore the effect of vaccine timing, treatment duration, age, vaccine type, and lymphocyte count on vaccine response. Results: Compared to no disease modifying therapy, the use of anti-CD20 monoclonal antibodies (odds ratio=0.03, 95% confidence interval [CI] = 0.01–0.06, p < 0.001) and fingolimod (odds ratio=0.04; 95% CI=0.01–0.12) were associated with lower seroconversion following the SARS-CoV-2 vaccine. All other drugs did not differ significantly from the untreated cohort. Both time since last anti-CD20 treatment and total time on treatment were significantly associated with the response to the vaccination. The vaccine type significantly predicted seroconversion, but not in those on anti-CD20 medications. Preliminary data on cellular T-cell immunity showed 40% of seronegative subjects had measurable anti-SARS-CoV-2 T cell responses. Interpretation: Some disease modifying therapies convey risk of attenuated serological response to SARS-CoV-2 vaccination in people with MS. We provide recommendations for the practical management of this patient group. ANN NEUROL 20219999:n/a–n/a.
Citation
Tallantyre, E. C., Vickaryous, N., Anderson, V., Asardag, A. N., Baker, D., Bestwick, J., …Dobson, R. (2022). COVID-19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology, 91(1), 89-100. https://doi.org/10.1002/ana.26251
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 18, 2021 |
Online Publication Date | Oct 22, 2021 |
Publication Date | Jan 1, 2022 |
Deposit Date | Nov 18, 2021 |
Publicly Available Date | Nov 18, 2021 |
Journal | Annals of Neurology |
Print ISSN | 0364-5134 |
Electronic ISSN | 1531-8249 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 91 |
Issue | 1 |
Pages | 89-100 |
DOI | https://doi.org/10.1002/ana.26251 |
Keywords | Clinical Neurology; Neurology |
Public URL | https://nottingham-repository.worktribe.com/output/6729552 |
Publisher URL | https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26251 |
Files
ana.26251
(705 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc/4.0/
You might also like
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
(2016)
Journal Article
The MRI central vein marker: differentiating PPMS from RRMS and ischaemic SVD
(2018)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search